Evidence map›Paper›PMID 33264486›Full record

ArticleMolecular oncology2021

Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR

Nadia Dandachi, Florian Posch, Ricarda Graf, Christoph Suppan, Eva Valentina Klocker, Hannah Deborah Müller, Jörg Lindenmann, Angelika Terbuch, Ellen Heitzer, Marija Balic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Review
  3. Observational
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nadia DandachiDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Austria.ORCID 0000-0001-9093-0743
Florian PoschDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Austria.
Ricarda GrafInstitute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Christian Doppler Laboratory for Liquid Biopsies for early Detection of Cancer, Medical University of Graz, Austria.
Christoph SuppanDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Austria.
Eva Valentina KlockerDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Austria.
Hannah Deborah MüllerDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Austria.
Jörg LindenmannDivison of Thoracic and Hyperbaric Surgery, Department of Surgery, Medical University of Graz, Austria.
Angelika TerbuchDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Austria.
Ellen HeitzerInstitute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Christian Doppler Laboratory for Liquid Biopsies for early Detection of Cancer, Medical University of Graz, Austria.
Marija BalicDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite improved clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitor treatment has limited the success of this treatment in HR

Indexed as

Genes, erbB-2Neoplasm MetastasisAgedAntineoplastic AgentsBreast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Disease ProgressionFemaleHumansLongitudinal StudiesMiddle AgedProof of Concept StudyProspective StudiesProtein Kinase InhibitorsTreatment OutcomeAntineoplastic AgentsCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsCDK4/6 therapycirculating tumor DNAjoint modellongitudinal biomarker analysismetastatic breast cancer

Identifiers

PMID33264486
PMCPMC8410553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.